FDA Approves Zirabev (bevacizumab-bvzr), a Biosimilar to Avastin
FDA Approves Zirabev (bevacizumab-bvzr), a Biosimilar to Avastin Print this page Friday, June 28, 2019 – Pfizer Inc. (NYSE:PFE) today announced the United States (U.S.) Food and Drug Administration(FDA) has approved Zirabev (bevacizumab-bvzr), a biosimilar to Avastin® (bevacizumab),1 for the treatment of five types of cancer: metastatic colorectal cancer; unresectable, locally advanced, recurrent or metastatic non-squamous non-small… Read More »